You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Commercialization Readiness Pilot for Amplifying Fibrinolysis in Ischemic Stroke

    SBC: TRANSLATIONAL SCIENCES INC            Topic: 103

    Ischemic stroke is the second leading cause of death and disability worldwide. Tissue plasminogen activator (TPA), the only approved treatment for ischemic stroke, dissolves the culprit fibrin thrombus to restore blood flow and relieve the brain from ischemia. Unfortunately, after prolonged ischemia, TPA restores full blood flow in only 30% of patients and may cause serious or fatal complications; ...

    SBIR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
  2. Lab on a chip point of care assay for the rapid serodiagnosis of Lyme disease

    SBC: IMMUNO TECHNOLOGIES INC            Topic: R

    DESCRIPTION Caused by Borrelia burgdorferi Lyme disease LD can affect the skin heart joints or nervous system leading to an array of largely non specific symptoms that overlap with those of other debilitating illnesses Disease progression can lead to development of conditions with unfavorable prognosis such as antibiotic refractory arthritis or Post Treatment Lyme disease Syndrome PTLDS ...

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Reducing Stroke by a Novel, Clot-dissolving Antibody

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NINDS

    DESCRIPTION (provided by applicant): Stroke is the 3rd leading cause of death and the primary cause of severe, long term disability. Each year 795,000 Americans have a stroke and the annual costs to the economy are 57.9 billion. The vast majority of acute ischemic strokes are caused by a thrombus (blood clot) which occludes the blood vessel and stops blood flow to the brain. Tissue plasminogen a ...

    SBIR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  4. Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    Each year venous thromboembolism affects up to 2 million Americans and 24 million people worldwide. Patients with venous thromboembolism have blood clots in the legs (venous thrombosis) that may travel to the lungs (pulmonary embolism). Pulmonary embolism (PE) is a leading cause of hospital deaths. Pulmonary emboli may acutely obstruct blood flow, causing right heart failure, circulatory collapse ...

    SBIR Phase II 2021 Department of Health and Human ServicesNational Institutes of Health
  5. HLS Potent, novel inhibitor of fibrinolytic hemorrhage- Phase II

    SBC: TRANSLATIONAL SCIENCES INC            Topic: NHLBI

    This SBIR Application is responsive to NHLBI Small Business Topics of Special Interest (therapeutics) that are of high programmatic interest (HLS-17-04). Hemorrhage or bleeding is a serious or fatal complication of surgery. Antifibrinolytic agents that inhibit plasmin-mediated fibrinolysis can significantly reduce blood loss, emergency reoperation, morbidity and death in patients with severe hemor ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  6. A Universal Brain Atlas for Implanting and Managing Deep Brain Stimulators

    SBC: Neurotargeting, LLC            Topic: NIMH

    DESCRIPTION (provided by applicant): Deep brain stimulation has risen as a neurosurgical procedure of choice for patients with disabling neurological or psychiatric disorders for its abiliy to modulate improvement in the activity of certain circuits. The procedure is currently approved for treatment of Parkinson's disease (PD), essential tremor (ET), dystonia, and obsessive-compulsive disorde ...

    STTR Phase II 2012 Department of Health and Human ServicesNational Institutes of Health
  7. Gene Expression and Diagnosis of Autoimmune Disease

    SBC: ARTHROCHIP, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Autoimmune diseases are thought to arise from abnormalities in innate or adaptive immune responses and most likely have both genetic and environmental components. Diagnosis of autoimmune disease is often difficult, as t he symptoms can be relatively nonspecific. Furthermore, no available blood test can accurately exclude the possibility of an autoimmune disease ...

    STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health
  8. Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents

    SBC: BIOVENTURES, INC            Topic: 172

    Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...

    STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  9. Lithium Oxyhalide Battery Separator Material

    SBC: ESPIN TECHNOLOGIES, INC.            Topic: MDA15027

    eSpin Technologies will design the scale up machine to produce novel high performance separator for lithium primary batteries. The process will be developed to produce novel separator and a variants which has the potential of a significantly higher volumetric efficiency for electrolyte storage capacity and kinetics to distribute electrolyte flow within nanoporous channel efficiently. This new sepa ...

    SBIR Phase II 2017 Department of DefenseMissile Defense Agency
  10. High Throughput, Label-Fee Molecular Interaction Platform for Membrane Protein

    SBC: MOLECULAR SENSING, INC.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Molecular interactions form the basis of healthy metabolism as well as the manifestation of disease, and comprise the very foundation of drug treatment. Tools available to study molecular interactions in their nascent environment and physiological concentrations without chemical modification, such as surface immobilization or labeling, are limited. Current labe ...

    SBIR Phase II 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government